What it's for (Indications)
- Atenolol is a cardioselective beta-1 adrenergic blocker primarily indicated for the management of essential hypertension, both alone and in combination with other antihypertensive agents, such as thiazide diuretics.
- It is also widely prescribed for the long-term prophylaxis of angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart muscle.
- Furthermore, atenolol is indicated for the early intervention and reduction of cardiovascular mortality in patients with suspected or definite acute myocardial infarction, aiding in the limitation of infarct size and reducing the incidence of reinfarction and ventricular fibrillation.
- Its use in these conditions aims to decrease cardiac workload and oxygen demand by reducing heart rate and myocardial contractility, thereby improving cardiac efficiency and symptom control.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of atenolol must be individualized based on the patient's clinical response and tolerability, always starting with the lowest effective dose. For the treatment of hypertension, the usual initial oral dose is 25 mg once daily, which can be increased to 50 mg once daily after one to two weeks, if necessary, to achieve the desired blood pressure control. Doses higher than 100 mg daily are generally not recommended as they typically do not produce further clinical benefit. For angina pectoris, the usual initial dose is 50 mg once daily, which may be increased to 100 mg once daily after one week, if required, for optimal symptom management. In patients with acute myocardial infarction, the typical regimen involves an initial intravenous dose, followed by oral administration. Renal impairment necessitates significant dosage adjustment, as atenolol is primarily renally excreted; dosing intervals may need to be extended or doses reduced. |
Safety & Warnings
Common Side Effects
- Atenolol, like other beta-blockers, can cause a range of side effects, some of which are common and generally mild, while others can be serious.
- Common adverse reactions include fatigue, dizziness, lightheadedness, bradycardia (slow heart rate), cold extremities, and gastrointestinal disturbances such as nausea, diarrhea, or constipation.
- More serious side effects, though less frequent, may include bronchospasm (especially in patients with pre-existing obstructive airway disease), exacerbation of heart failure, severe bradycardia or heart block requiring intervention, and profound hypotension.
- Central nervous system effects such as depression, nightmares, and insomnia have also been reported, particularly in susceptible individuals.
- Patients should be advised to report any persistent or worsening symptoms to their healthcare provider promptly.
- Allergic reactions, though rare, can manifest as rash, pruritus, or angioedema.
Serious Warnings
- Black Box Warning: **BLACK BOX WARNING: ABRUPT CESSATION OF ATENOLOL THERAPY** **DO NOT ABRUPTLY DISCONTINUE ATENOLOL THERAPY.** Following abrupt cessation of therapy with beta-blockers, including atenolol, exacerbations of angina pectoris and, in some cases, myocardial infarction and ventricular arrhythmias have been observed. This risk is particularly elevated in patients with underlying coronary artery disease. Therefore, when discontinuing chronically administered atenolol, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of one to two weeks. During this period, patients should be carefully monitored, and if angina worsens or acute coronary insufficiency develops, atenolol administration should be reinstituted promptly, at least temporarily, or other measures appropriate for the management of unstable angina should be taken. Since coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue atenolol therapy abruptly even in patients treated only for hypertension. Patients should be explicitly warned against interrupting or discontinuing therapy without physician advice. This gradual tapering is critical to minimize the risk of serious cardiovascular events related to sympathetic overactivity following withdrawal.
- Several significant warnings are associated with atenolol use.
- Patients with bronchospastic diseases, such as asthma or chronic obstructive pulmonary disease (COPD), should generally not receive beta-blockers due to the risk of exacerbating bronchospasm; if absolutely necessary, a cardioselective beta-blocker like atenolol should be used with extreme caution and at the lowest effective dose.
- Atenolol can mask symptoms of hypoglycemia in diabetic patients, potentially delaying recognition and treatment of critically low blood sugar.
- It can also mask signs of hyperthyroidism, such as tachycardia, and abrupt withdrawal can precipitate thyroid storm.
- Caution is advised in patients with peripheral vascular disease due to potential worsening of symptoms.
- Atenolol is primarily excreted via the kidneys, so dosage adjustments are crucial in patients with renal impairment to prevent accumulation and adverse effects, requiring careful monitoring of renal function.
- Abrupt discontinuation of atenolol, particularly in patients with ischemic heart disease, can lead to exacerbation of angina, myocardial infarction, and ventricular arrhythmias, necessitating gradual withdrawal as outlined in the Black Box Warning.
How it Works (Mechanism of Action)
Atenolol is a selective beta-1 adrenergic receptor blocker. Its primary mechanism of action involves competitively blocking beta-1 adrenergic receptors, predominantly located in the heart. This blockade leads to a reduction in heart rate, myocardial contractility, and cardiac output, thereby decreasing myocardial oxygen demand. By reducing cardiac output and inhibiting renin release from the kidneys, atenolol contributes to the lowering of blood pressure. Unlike non-selective beta-blockers, atenolol has minimal activity at beta-2 adrenergic receptors, which are found in the bronchial and vascular smooth muscle, conferring a degree of cardioselectivity. This property makes it relatively safer for patients with obstructive airway diseases, although this selectivity is dose-dependent and can be lost at higher doses. Its hydrophilic nature means it penetrates the blood-brain barrier poorly compared to lipophilic beta-blockers, potentially leading to fewer central nervous system side effects.